MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Botwright et al. presented a comprehensive report by a multinational task force outlining good practices for developing health technology assessment (HTA) guidelines. The study aimed to enhance transparency and legitimacy in HTA decision-making across diverse country contexts. Key recommendations address the full guideline development cycle, emphasizing content development, stakeholder engagement, institutional arrangements, and monitoring guideline implementation success.

In May 2025, the Danish Health Authority proposed three key initiatives in the health reform that will future-proof the healthcare system, including the National Health Plan, the Task description for general practice services, and the Package pathway for people with chronic diseases. The Danish Health Authority expects to hand over the first assignments in the autumn of 2025. The new structure of the healthcare system is expected to come into force on January 1, 2027.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Merész et al. examined the implementation of the EU HTA Regulation from the perspective of public health decision-makers in Central European member states. Their study highlighted both opportunities for enhanced cooperation and challenges related to timelines and scope differences across member states. The authors concluded that while foundations for successful collaboration exist, policymakers and payers must share the responsibility of acting as drivers of change in health policy to reduce duplication of efforts by health technology developers.

MTRC is pleased to introduce a new service to help bridge the gap between clinical research and the evidence expectations of European HTA and reimbursement bodies.

In May 2025, the Ministry of Health, Welfare, and Sport provided further details on terminating "Subsidy Scheme for Promising Care". The program will be discontinued as of January 1, 2026, without any follow-up measures or financing. No new rounds for submission of proposals will be available. Nothing will change for the 28 ongoing projects and projects expected to be awarded later in 2025 as a result of the last completed rounds.

On May 6, 2025, NHS England issued an updated version of the National Genomic Test Directory for 2025/26, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. One new code (test-indication combination) was introduced in the Test Directory for cancer, and one for rare and inherited diseases.

On April 22, 2025, the Innovation Committee at the Federal Joint Committee (G-BA) announced the receipt of 156 applications (project ideas) for innovation funding of projects for new forms of care. The majority of applications (n=117) were submitted in response to topic-specific funding calls, including integration of AI systems into healthcare structures and processes, strengthening child and youth health, and women's health. A decision on which project ideas will be invited to submit full proposals is expected in the fourth quarter of 2025.

On April 30, 2025, the Federal Council approved the new outpatient reimbursement system, comprising the TARDOC catalog of individual service tariffs (ambulatory settings) and the flat-rate system (day case settings). The approval is valid until December 31, 2028, allowing for potential adjustments post-implementation. The TARDOC and outpatient flat rates will take effect on January 1, 2026.

MTRC is pleased to announce the release of its latest White Paper: "Best Reporting Checklists for Studies of Medical Devices". This White Paper explores the best reporting checklists for medical device studies (CONSORT, STROBE, STARD, PRISMA, PRISMA-DTA, SPIRIT, and TIDieR), their key components, and how they improve research transparency.

MTRC is pleased to announce the release of its latest White Paper: "General Market Access Landscape for Health Apps in Europe". This document provides a structured overview of the reimbursement landscape for health apps in three major European countries: England, France, and Germany.

In March-April 2025, Health Technology Wales (HTW) accomplished one full appraisal of permanent implant brachytherapy devices for unresectable pancreatic cancer. Five Med Tech-related Topic Exploration Reports were published (on superior rectal artery embolization, glucose monitoring systems in neonates, gender-affirming surgery, telemetric intracranial pressure monitoring, tumor-profiling tests to guide bisphosphonate treatment in cancer).

Meet MTRC’s Senior Reimbursement Consultant, Julia Mazur, at the Pharma 4.0 - Digital Healthcare Conference in Berlin. Visit us at Booth #9 to explore tailored solutions in market access, health economics, and evidence synthesis for complex MedTech challenges. Don’t miss Dr. Borisenko’s expert talk on the reimbursement of digital technologies in Europe on 22 May at 10:50 AM.